Medical Developments International Limited

As of June 30, 2025, Medical Developments International Limited carries a market capitalization of 61.96M, placing it among publicly traded companies globally. Its enterprise value stands at 46.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medical Developments International Limited's next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2025, Medical Developments International Limited has 112.66M shares outstanding.

As of June 30, 2025, Medical Developments International Limited trades at a trailing price-to-earnings ratio of 643.57. The price-to-sales ratio is 1.55, and the price-to-book ratio stands at 1.12.

As of June 30, 2025, Medical Developments International Limited trades at an EV/EBITDA multiple of 31.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 46.12M versus a market cap of 61.96M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Medical Developments International Limited maintains a current ratio of 4.54, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.61, indicating elevated leverage, while an interest coverage ratio of 19.24 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Medical Developments International Limited posted a return on equity (ROE) of 0.19, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -1.87, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.15, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.26, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.06 indicates how many times Medical Developments International Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Medical Developments International Limited recorded 74,000.00 in income tax expense. That works out to an effective tax rate of 44.05, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 168,000.00, leaving 94,000.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Medical Developments International Limited's stock has declined approximately 44.29% over the past 52 weeks. The 50-day moving average sits at 0.46, while the 200-day moving average is 0.44.

Over the twelve months ended June 30, 2025, Medical Developments International Limited generated 39.06M in revenue and converted that into 94,000.00 in net income, yielding earnings per share of 0.00. EBITDA reached 1.44M, while operating income came in at -1.76M.

As of June 30, 2025, Medical Developments International Limited holds 17.84M in cash and equivalents against 1.99M in total debt, resulting in a net debt position of -17.84M. Total book value stands at 55.10M, with working capital of 27.72M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Medical Developments International Limited posted a gross margin of 75.35, reflecting its pricing power and cost economics. The operating margin of -4.51 and net profit margin of 0.24 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -14.01, meaning Medical Developments International Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Medical Developments International Limited's most recent stock split took place on July 30, 2024 with a 263:270 split ratio.

As of June 30, 2025, Medical Developments International Limited has an Altman Z-Score of 2.81, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.